论文信息 - Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. - 字舞流文

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine | S. Jagannath | A. Jakubowiak | S. Lonial | N. Munshi | P. Richardson | N. Raje | T. Hideshima | I. Ghobrial | D. Vesole | R. Knight | A. Mazumder | M. McKenney | M. Alsina | K. Colson | S. Kennedy | K. Anderson | L. Lunde | C. Mitsiades | K. Kosakowski | M. Mckenney